Jeannine Madere Email

Director Clinical Operations . Treadwell Therapeutics

Current Roles

Employees:
56
Revenue:
$4.3M
About
Treadwell Therapeutics is a clinical-stage biotechnology company developing novel therapeutics for highly aggressive cancers by targeting critical tumor-specific vulnerabilities including aneuploidy and immunogenicity. The Company’s robust, internally developed pipeline includes novel small molecule drugs in single agent and combination studies. Lead candidate, CFI-400945, is a PLK4 inhibitor in multiple Phase 1 and Phase 2 trials including for TNBC, prostate cancer and AML. Additional product candidates include CFI-402257, a clinical stage TTK inhibitor, as well as CFI-402411, a preclinical HPK1 inhibitor (IND filing 1H20), which is positioned to be the first clinical stage small molecule modulator of a unique node of T cell activation and has a mechanism distinct from PD1/PDL1. Interested in joining Treadwell Therapeutics? Visit our Career page: https://treadwelltx.com/careers/
Treadwell Therapeutics Address
777 Mariners Island Blvd
New York, NY
USA
Treadwell Therapeutics Email

Past Companies

Treadwell Therapeutics, Inc.Director Clinical Operations
Acerta Pharma B.V. (A member of the AstraZeneca Group)Director Clinical Operations
Acerta Pharma B.V. (A member of the AstraZeneca Group)Associate Director, Clinical Operations

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.